share_log

Voyager Therapeutics (NASDAQ:VYGR) Shareholder Returns Have Been Favorable, Earning 71% in 1 Year

Voyager Therapeutics (NASDAQ:VYGR) Shareholder Returns Have Been Favorable, Earning 71% in 1 Year

Voyager Therapeutics(纳斯达克股票代码:VYGR)股东回报良好,1年内收益71%
Simply Wall St ·  01/04 10:11

The simplest way to invest in stocks is to buy exchange traded funds. But you can significantly boost your returns by picking above-average stocks. For example, the Voyager Therapeutics, Inc. (NASDAQ:VYGR) share price is up 71% in the last 1 year, clearly besting the market return of around 23% (not including dividends). That's a solid performance by our standards! Also impressive, the stock is up 31% over three years, making long term shareholders happy, too.

投资股票的最简单方法是购买交易所交易基金。但是,您可以通过选择高于平均水平的股票来显著提高回报。例如,Voyager Therapeutics, Inc.(纳斯达克股票代码:VYGR)的股价在过去1年中上涨了71%,显然超过了约23%(不包括股息)的市场回报率。按照我们的标准,这是一项不错的表现!同样令人印象深刻的是,该股在三年内上涨了31%,这也使长期股东感到高兴。

Since it's been a strong week for Voyager Therapeutics shareholders, let's have a look at trend of the longer term fundamentals.

由于对于Voyager Therapeutics的股东来说,这是强劲的一周,让我们来看看长期基本面的趋势。

View our latest analysis for Voyager Therapeutics

查看我们对 Voyager Therapeutics 的最新分析

To quote Buffett, 'Ships will sail around the world but the Flat Earth Society will flourish. There will continue to be wide discrepancies between price and value in the marketplace...' By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time.

引用巴菲特的话说:“船只将在世界各地航行,但平地协会将蓬勃发展。市场上的价格和价值之间将继续存在巨大差异...”通过比较每股收益(EPS)和股价随时间推移的变化,我们可以了解投资者对公司的态度如何随着时间的推移而变化。

During the last year Voyager Therapeutics grew its earnings per share, moving from a loss to a profit.

去年,Voyager Therapeutics增加了每股收益,从亏损转为盈利。

When a company has just transitioned to profitability, earnings per share growth is not always the best way to look at the share price action.

当一家公司刚刚过渡到盈利时,每股收益的增长并不总是看待股价走势的最佳方式。

However the year on year revenue growth of 125% would help. Many businesses do go through a phase where they have to forgo some profits to drive business development, and sometimes its for the best.

但是,125%的收入同比增长将有所帮助。许多企业确实经历了一个必须放弃一些利润来推动业务发展的阶段,有时这是最好的选择。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下图中查看收入和收入随着时间的推移而发生的变化(点击图表查看确切的数值)。

earnings-and-revenue-growth
NasdaqGS:VYGR Earnings and Revenue Growth January 4th 2024
NASDAQGS: VYGR 收益和收入增长 2024 年 1 月 4 日

We know that Voyager Therapeutics has improved its bottom line lately, but what does the future have in store? You can see what analysts are predicting for Voyager Therapeutics in this interactive graph of future profit estimates.

我们知道Voyager Therapeutics最近提高了利润,但是未来会发生什么?在这张未来利润估计的交互式图表中,你可以看到分析师对Voyager Therapeutics的预测。

A Different Perspective

不同的视角

We're pleased to report that Voyager Therapeutics shareholders have received a total shareholder return of 71% over one year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 3% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. For example, we've discovered 2 warning signs for Voyager Therapeutics (1 is significant!) that you should be aware of before investing here.

我们很高兴地向大家报告,Voyager Therapeutics的股东在一年内获得了71%的总股东回报率。由于一年期股东总回报率好于五年期股东总回报率(后者为每年3%),因此该股的表现似乎在最近有所改善。鉴于股价势头仍然强劲,可能值得仔细研究该股,以免错过机会。我发现将长期股价视为业务绩效的代表非常有趣。但是,要真正获得见解,我们还需要考虑其他信息。例如,我们发现了 Voyager Therapeutics 的 2 个警告信号(1 个很重要!)在这里投资之前,您应该注意这一点。

We will like Voyager Therapeutics better if we see some big insider buys. While we wait, check out this free list of growing companies with considerable, recent, insider buying.

如果我们看到一些重大的内幕收购,我们会更喜欢Voyager Therapeutics。在我们等待的同时,请查看这份免费清单,列出了最近有大量内幕收购的成长型公司。

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

请注意,本文引用的市场回报反映了目前在美国交易所交易的股票的市场加权平均回报率。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

对这篇文章有反馈吗?对内容感到担忧?直接联系我们。 或者,给编辑团队 (at) simplywallst.com 发送电子邮件。
Simply Wall St 的这篇文章本质上是笼统的。我们仅使用公正的方法提供基于历史数据和分析师预测的评论,我们的文章并非旨在提供财务建议。它不构成买入或卖出任何股票的建议,也没有考虑到您的目标或财务状况。我们的目标是为您提供由基本数据驱动的长期重点分析。请注意,我们的分析可能不会考虑最新的价格敏感型公司公告或定性材料。华尔街只是没有持有上述任何股票的头寸。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发